相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
Thomas Winkler et al.
BLOOD (2019)
Thrombopoietin receptor agonists: ten years later
Waleed Ghanima et al.
HAEMATOLOGICA (2019)
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
Jong Wook Lee et al.
LANCET HAEMATOLOGY (2019)
Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia
Lin-Pierre Zhao et al.
BONE MARROW TRANSPLANTATION (2019)
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
Etienne Lengline et al.
HAEMATOLOGICA (2018)
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
Etienne Lengline et al.
HAEMATOLOGICA (2018)
Aplastic Anemia
Neal S. Young
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activity of eltrombopag in severe aplastic anemia
Phillip Scheinberg
BLOOD ADVANCES (2018)
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
Silvia Cantoni et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia
Harinder Gill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Danielle M. Townsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Evangelia Vlachodimitropoulou et al.
BLOOD (2017)
Guidelines for the diagnosis and management of adult aplastic anaemia
Sally B. Killick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
David J. Kuter et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
Jose Ramon Gonzalez-Porras et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Ronan Desmond et al.
BLOOD (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia
Mehdi Khellaf et al.
HAEMATOLOGICA (2013)
The optimal immunosuppressive therapy for aplastic anemia
Seung Hwan Shin et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation
Michael Roth et al.
BLOOD (2012)
Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Matthew J. Olnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura
Ekaterina Gibiansky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
Connie L. Erickson-Miller et al.
STEM CELLS (2009)
Historical review: megakaryopoiesis and thrombopoiesis
Kenneth Kaushansky
BLOOD (2008)
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
Julian M. Jenkins et al.
BLOOD (2007)
分享论文
